Home : Unsafe Drugs : Bextra
Bextra
Bextra, or valdecoxib, is an anti-inflammatory drug used to treat symptoms of osteoarthritis and rheumatoid arthritis and to relieve painful menstrual cramps. Pfizer voluntarily withdrew Bextra from the market in 2005, after use of Bextra was shown to increase the risk of cardiovascular events, including heart attack and stroke. Bextra has also been linked to Stevens-Johnson syndrome, a sometimes fatal skin disease. SJS causes painful blistering and erosion of skin, rashes, and selling of skin and mucous membranes.
Fast Facts
| Name: | Bextra |
| Generic: | Valdecoxib |
| Manufacturer: | Pfizer, Inc. |
| Date approved: | November 2001 |
| Status: | Voluntarily withdrawn by manufacturer |
| Approved uses: | Treating symptoms of osteoarthritis and rheumatoid arthritis in adults and in relieving painful menstrual cycles |
| Off-Label uses: | General pain relief |
| Side effects: | Increased risk of cardiovascular events including heart attack and stroke when used in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs). Stevens-Johnson syndrome, a rare, sometimes fatal, skin disease has been linked to Bextra. |
| Related topics: | Unsafe drugs, Stevens Johnson syndrome |
Pfizer Respectfully Disagrees with FDA Decision on Bextra
In April 2005, the Federal Drug & Food Administration (FDA) asked Pfizer Inc. to suspend sales of Bextra. Pfizer halted the sales of Bextra because the FDA determined that the health risks... read more
Bextra Still Off the Market
Bextra®, generic name Valdecoxib, is a prescription COX-2 selective non-steroidal anti-inflammatory drug (NSAID) manufactured by Pfizer, Inc . On April 7,... read more
View the Bextra Main Articles page here
Videos Related to Bextra
Information about Bextra Lawsuits
View the Bextra Videos page here
FDA Information Related to Bextra
Alert for Healthcare Professionals: Valdecoxib (marketed as Bextra)
CDER NME Approvals in Calendar Year 2001
View the Bextra FDA Information page here
MSN Newsfeeds Related to Bextra
Web Exclusive: GEN's Annual Wall Street Roundup
Weitz & Luxenberg Echoes Growing Concern over New Warning on Ortho ...
View the Bextra MSN Newsfeeds page here
News Articles Related to Bextra
Letters: Taking the temperature on polyclinics | Society | The Guardian
NHS reforms offer more choice, but more miles to travel - Times Online
View the Bextra News Articles page here
Patents Related to Bextra
Substituted isoxazoles for the treatment of inflammation
View the Bextra Patents page here
Useful Web Sites Related to Bextra
James F. Humphreys, LC, Bextra
Burg Simpson, Unsafe Drugs Attorneys
View the Bextra Useful Web Sites page here
Wikipedia Entries Related to Bextra
View the Bextra Wikipedia Entries page here
Books Related to Bextra
COX-2 inhibitors: what you need to know. : An article from: National Women's Health Report
Bextra woes boost rivals as treatment options narrow : An article from: Medical Marketing and Media
View the Bextra Books page here
